Cytomorphologic and Immunophenotypical analysis of SMARCA4 (BRG1)-Deficient Non-small Cell Lung Carcinoma
The eJournal is an online pathology journal club that reviews current articles from a peer-reviewed cytopathology Journal.
Participants will be able to review the journal article, commentary and webinar from the contributing author. This is a great self-assessment, teaching and continuing education tool.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
- To determine the utility of identifying patient’s with SMARCA4 (BRG1) deficient non small cell lung carcinoma (SMARCA4-dNSCLC)
- To evaluate the cytomorphology and immunohistochemical profile of SMARCA4-dNSCLC
- To examine the benefit of identifications of tumors with SMARCA4 alterations
Sadia Sayeed, MD
Oluwaseun B. Ogunbona, MD
PhD, Xiaoqi Lin, MD, PhD
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.
The following individuals have reported financial relationships:
Oscar Lin MD PhD: Consultant – Hologic and Jansen
Liron Pantanowitz MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B Pitman MD FIAC: Consultant – Adenocyte, LLC
Donna K. Russell MEd CT(ASCP) HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche MD PhD: Ad hoc advisory board panel and Consultant – Roche
The following individuals have reported no relevant financial relationships:
Susan A. Alperstein, MS, CT(ASCP), Fatima Z. Aly, MD, PhD, Tatjana Antic, MD, Kristen A. Atkins, MD, Guliz A. Barkan, MD, Christine N. Booth, MD, Barbara A. Centeno, MD, Aastha Chauhan, MD, Jeanine M. Chiaffarano, DO, Paul Z. Chiou, MPH, SCT(ASCP), Deborah J. Chute, MD, Amy C. Clayton, MD, Jacqueline M. Cuda, BS, SCT(ASCP), Kara L. Hansing, MEd, SCT(ASCP)CM, Melissa Hogan, MD, Seema Khutti, MBBS, Xiaoqi Lin, MD, PhD, Patrick McIntire, MD, Sanjana Mehrotra, MD, Sara E. Monaco, MD, Seyedreza Mousavi, MD, MS, Ranjana S. Nawgiri, MD, M. Katayoon Rezaei, MD, Esther D. Rossi, MD, PhD, Sinchita Roy-Chowdhuri, MD, PhD, Sadia Sayeed, MD, Momin T. Siddiqui, MD, FIAC, Swikrity Upadhyay Baskota, MD, Saloni Walia, MD
The ASC staff associated with the development of content for this activity reported no relevant financial relationships.
Presenters: The presenters have no conflicts of interest or financial relationships to disclose.
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Continuing Certification (CC)
This product can help fulfill the CME requirements and Self-Assessment Modules (SAMs) mandated by the American Board of Pathology Continuing Certification (CC) process. Earn up to 1.0 SAM Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 1.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 1 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the presentation date.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 California Credits
- 1.00 CMLE
- 1.00 Florida Credits
- 1.00 MOC II
- 1.00 Participant